Iridex Glaucoma Laser Study Shows Two-Year Pressure Reduction

Iridex Corporation (IRIX) announced two-year study results showing sustained improvements for glaucoma patients treated with its MicroPulse transscleral laser therapy. The retrospective study tracked 84 eyes across 53 patients receiving treatment with the company's Cyclo G6 Laser and MicroPulse P3 Delivery Device. Over 24 months, average intraocular pressure dropped from 22.32 mmHg to 14.05 mmHg, while average daily eye drop medications fell from 2.96 to 2.38.

The study recorded success rates of 86% in primary open-angle glaucoma eyes and 81% in primary angle-closure glaucoma eyes, with zero reported complications or vision losses. In addition, all patients taking oral acetazolamide prior to treatment stopped taking the medication entirely during the follow-up period. These findings indicate that the laser therapy can effectively treat patients at earlier stages of glaucoma while easing their ongoing medication burden.

Investors should monitor whether these multi-year clinical findings encourage wider adoption among eye care specialists and support commercial expansion of Iridex product lines. Tracking future clinical publications and upcoming quarterly financial results will provide clarity on whether clinical validation translates into broader market growth for the medical device maker.